August 2016

Solutions for Reducing Patient Cost Sharing for Medications

August 16, 2016

Evidence-Based Oncology

Cost sharing for medications presents a serious access barrier for many blood cancer patients. Available solutions, if embraced by policymakers, could reduce such cost sharing with very little impact on premiums.

Charitable Assistance Among Economically Vulnerable Cancer Patients: Patient Access Network Foundation Summary Statistics 2011-2015

August 18, 2016

Evidence-Based Oncology

This report shows that among people who are eligible for charitable assistance to cover out-of-pocket (OOP) prescription drug expenses, those with cancer have higher per-claim and per-person OOP costs than their counterparts with other health conditions.

Does the Cost-Sharing Burden Influence Cancer Outcomes?

August 19, 2016

Evidence-Based Oncology

Financial burden is a potential nonclinical adverse event in cancer patients. As patients, especially those in the lower income ranges and the middle class, struggle to meet their medical bills, the likelihood of them skipping doses or doctor’s visits is quite high.

Improve Medicare Policy to Remove Barriers to Bone Marrow and Cord Blood Transplants

August 19, 2016

Evidence-Based Oncology

Reducing barriers to hematopoetic stem cell (HPC) transplant is critical to supporting patients with one of the more than 70 blood cancers and other blood disorders (such as leukemia, lymphoma, and myloplastic dysplasia) for which a transplant may be the only therapy remaining with curative intent.

Proton Therapy Eliminates Unnecessary Radiation Exposure and Is Medically Necessary

August 19, 2016

Evidence-Based Oncology

When it comes to health coverage, most Americans face an unnerving reality-they have no idea what is covered under their health insurance policy until after they are affected by illness or disease.

Finding Solutions for Cancer Patients: The American Cancer Society's Health Insurance Assistance Service

August 19, 2016

Evidence-Based Oncology

Since 2005, American Cancer Society has sponsored the Health Insurance Assistance Service, a unique initiative to help cancer patients navigate the private coverage system and to educate policy makers about how coverage works for patients with this serious and chronic condition.

Precision Oncology: Why Payers Should Initiate CGP Coverage Now!

August 19, 2016

Evidence-Based Oncology

Precision oncology, or the clinically and financially efficient use of genomically matched treatments and clinical trials, is evolving as a potentially important starting point for cancer care within successful alternative payment models.

Young Adult Cancer Survivors Disproportionately Affected by Treatment Costs

August 19, 2016

Evidence-Based Oncology

Young adult (YA) cancer survivors are hit the hardest in the wallet by their treatment. The average net worth of YAs who have received grants from The Samfund is a staggering —$35,000, while their counterparts in the general population is $68,000

Patient Access to Reference Pricing Prompts Choice of Lower-Cost Testing Laboratories, Cost Savings

August 19, 2016

Evidence-Based Oncology

A study by researchers at the University of California, Berkeley, found that patients who have access to the prices charged by a testing laboratory, as well as reference pricing, choose lower-cost laboratories, a move that results in overall cost savings.

California Experiment Will Let Pathologists Report Cancer Diagnoses in Real Time

August 19, 2016

Evidence-Based Oncology

A collaborative pilot that involves the California Department of Public Health, St. Joseph Health in Orange County, and UCSF Benioff Children’s Hospital in Oakland is studying whether near—real-time reporting of cancer diagnoses by pathologists, using standardized electronic forms, will permit providers to make more informed and timely treatment decisions.

Breakthrough for Daratumumab for Use as Second-Line Treatment With Standard of Care in Multiple Myeloma

August 19, 2016

Evidence-Based Oncology

The monoclonal antibody daratumumab (Darzalex) has been granted Breakthrough designation, the second for this drug, for use in combination with either lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with multiple myeloma who have received at least 1 prior therapy.

NEJM Study First to Identify Mutations Responsible for Relapse in PD-1 Inhibitor—Treated Melanoma

August 19, 2016

Evidence-Based Oncology

Loss-of-function mutations in Janus kinase 1 (JAK1) or Janus kinase 2 (JAK2), deletion of the wild-type allele of JAK1 or JAK2, and truncation in the antigen-presenting protein beta-2-microglobulin (B2M) gene have been found responsible for lack of response to interferon gamma in patients with melanoma.

Nivolumab Passes QOL Test in Melanoma

August 19, 2016

Evidence-Based Oncology

Results from the CheckMate 066 study found that the checkpoint inhibitor nivolumab, which has proven highly efficient in the treatment of melanoma, also performs well in improving the patient’s long-term quality of survival benefit in patients with advanced melanoma.

The Risk of T2D in Individuals With Benign Adrenal Tumors

August 19, 2016

Evidence-Based Oncology

Adrenal gland tumors that are defined as being nonfunctional may not really be so, and the hormones that these tumors secrete could increase an individual’s risk of cardiometabolic irregularities, according to a new study.

Paying to Make Health IT Meaningful: A Discussion at the NCCN Policy Summit

August 19, 2016

Evidence-Based Oncology

Maximizing the utility of technology platforms and making them meaningful to ensure quality cancer care was the underlying theme of Emerging Issues and Opportunities in Health Information Technology, a National Comprehensive Cancer Network Policy Summit, held June 27, 2016, in Washington, DC.

Health IT Essential for the Success of Cancer Moonshot

August 19, 2016

Evidence-Based Oncology

Gregory C. Simon, executive director, White House Cancer Task Force, spoke at the National Comprehensive Cancer Network Policy Summit in Washington, DC. “Just like the original moonshot, the Cancer Moonshot is about using technology and the resulting information,” he said.

Dissolving Data Silos and Improving Access to Health IT Essential in Oncology Care

August 19, 2016

Evidence-Based Oncology

At the Emerging Issues and Opportunities in Health Information Technology Policy Summit hosted by the National Comprehensive Cancer Network, on June 27, 2016, an afternoon panel discussed the role of technology and its importance in promoting dissemination of data.